Search - tctmd.com

Displaying 1 - 20 of 84

Sort: Relevancy | Date

Presentation TCT 2025

Abluminus Sirolimus DES+ vs. Everolimus-Eluting Stents in Patients with Diabetes Mellitus: Final 2-Year Results of the ABILITY Global Study

Presenter: Alexandre Abizaid

October 25, 2025

Presentation TCT 2024

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

Presenter: Woo Jin Ahn

October 29, 2024

Presentation EuroPCR 2024

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

Presenter: Alexandre Abizaid

May 14, 2024

Presentation TCT 2023

TCT 677: Direct Comparison of Zotarolimus Eluting Stents vs Everolimus Eluting Stents Stratified by Follow-ups: An Updated Meta-analysis of Randomized Controlled Trials

Presenter: Usman Naseer

October 25, 2023

Presentation TCT 2023

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

Presenter: Juan Iglesias

October 25, 2023

Presentation TCT 2023

Polymer-Free Amphilimus-Eluting Stents vs. Biodegradable-Polymer Everolimus-Eluting Stents in All-Comers Undergoing PCI: 1-Year Results of the PARTHENOPE Trial

Presenter: Giovanni Esposito

October 25, 2023

Presentation TCT 2022

Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled BEST Trial

Presenter: Jung-Min Ahn

September 19, 2022

Presentation TCT 2021

TIDES-ACS: Three-Year Outcomes From a Randomized Trial of Titanium Nitride Oxide-Coated Versus Everolimus-eluting Stents in Patients With Acute Coronary Syndromes

Presenter: Pasi Karjalainen

November 06, 2021

Presentation TCT 2020

TCT 276: A 'Real-World' Multi-center Registry Evaluating Safety and Clinical Performance of Biodegradable Polymer-coated Ultra-thin Everolimus-eluting Stents: 3-year Results from the PERFORM-EVER Registry

Presenter: Sridhar Kasturi, MD

October 14, 2020

Presentation TCT Abstracts Posters 2019

A 'Real-World' Multi-center Registry Evaluating Safety and Clinical Performance of Biodegradable Polymer Coated Ultra-Thin Everolimus-Eluting Stents: One-year Results From the PERFORM-EVER Registry

Presenter: Sridhar Kasturi

October 09, 2019

Presentation TCT 2019

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

Presenter: Run-Lin Gao

September 25, 2019

Presentation TCT 2019

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

Presenter: Jens Wiebe

September 25, 2019

Presentation CIT 2019

A Randomized Trial Comparing a Novel Sirolimus-Eluting Bioresorbable Scaffold with Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease: Three-Year Results of NeoVas RCT

Presenter: Yaling Han

March 28, 2019

Presentation JIM 2019

TALENT: Thin strut sirolimus-eluting stent in all comers population vs Everolimus-eluting stent

Presenter: Giuseppe Tarantini

February 14, 2019

Presentation TCT 2018

RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease

Presenter: James B. Hermiller Jr, Hiroki Shiomi

September 25, 2018

Presentation TCT 2018

TCT-1: Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

Presenter: Steven R. Bailey, Patrick W. Serruys, Sorin J. Brener

September 22, 2018

Presentation TCT 2018

TCT-91: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis

Presenter: Alexandre Abizaid, Didier Carrié, Ariel Roguin

September 21, 2018

Presentation TCT 2017

Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

Presenter: Stephen G. Ellis, David E. Kandzari, Sigmund Silber

October 30, 2017

Presentation TCT 2017

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Presenter: Stephen G. Ellis, David E. Kandzari, Tullio Palmerini

October 30, 2017

Presentation ESC 2017

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

Presenter: David E Kandzari

September 13, 2017

Advertisement

Abluminus Sirolimus DES+ vs. Everolimus-Eluting Stents in Patients with Diabetes Mellitus: Final 2-Year Results of the ABILITY Global Study

TCT 427: Comparison of Clinical Outcomes Between Second Generation Zotarolimus- Versus Everolimus-Eluting Stents up to 10-Year Follow-up

Randomised comparison of Abluminus DES+ sirolimus-eluting stents versus everolimus-eluting stents in coronary artery disease patients with diabetes mellitus global: the ABILITY diabetes global study

TCT 677: Direct Comparison of Zotarolimus Eluting Stents vs Everolimus Eluting Stents Stratified by Follow-ups: An Updated Meta-analysis of Randomized Controlled Trials

Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the Biostemi Randomized Trial

Polymer-Free Amphilimus-Eluting Stents vs. Biodegradable-Polymer Everolimus-Eluting Stents in All-Comers Undergoing PCI: 1-Year Results of the PARTHENOPE Trial

Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled BEST Trial

TIDES-ACS: Three-Year Outcomes From a Randomized Trial of Titanium Nitride Oxide-Coated Versus Everolimus-eluting Stents in Patients With Acute Coronary Syndromes

TCT 276: A 'Real-World' Multi-center Registry Evaluating Safety and Clinical Performance of Biodegradable Polymer-coated Ultra-thin Everolimus-eluting Stents: 3-year Results from the PERFORM-EVER Registry

A 'Real-World' Multi-center Registry Evaluating Safety and Clinical Performance of Biodegradable Polymer Coated Ultra-Thin Everolimus-Eluting Stents: One-year Results From the PERFORM-EVER Registry

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

A Randomized Trial Comparing a Novel Sirolimus-Eluting Bioresorbable Scaffold with Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease: Three-Year Results of NeoVas RCT

TALENT: Thin strut sirolimus-eluting stent in all comers population vs Everolimus-eluting stent

RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease

TCT-1: Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

TCT-91: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis

Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content